Clinical trials: Proliferative Diabetic Retinopathy
Diabetic Vitreous Hemorrhage, Intravitreal Injections
Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage
This prospective interventional cohort study evaluates the outcomes of intravitreal ranibizumab injection in patients with diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy.
- Conditions
- Diabetic Vitreous Hemorrhage, Intravitreal Injections, Ranibizumab
- Trial name
- RANI-VH (NCT07690800)
- Testing
- Ranibizumab
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Benha University
Proliferative Diabetic Retinopathy
Retinal Laser by Multi-spot Photocoagulator and Driving Eligibility
The purpose of this study is to determine the risk of failing the visual field criteria to hold a driving license following retinal laser treatment delivered with a multi-spot photocoagulator.
- Trial name
- NCT01383772
- Testing
- Pan retinal Photocoagulation
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Proliferative Diabetic Retinopathy
A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)
The pilot study evaluates the efficacy and safety of Canakinumab (ILARIS®) in subjects with proliferative diabetic retinopathy secondary to type 1 and 2 diabetes.
- Trial name
- ILARIS (NCT01589029)
- Testing
- CANAKINUMAB (ILARIS®)
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- PD Dr. med. Stephan Michels
Diabetic Non-proliferative Retinopathy, Type2 Diabetes
Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
This study include 384 Participants with diabetic non-proliferative retinopathy Design Method: Randomized, double blind, placebo controlled and multicenter clinical study.
- Trial name
- NCT03025399
- Testing
- Tangwang prescription
- Volunteers
- 384 people
- Sponsor
- Fengmei Lian
Proliferative Diabetic Retinopathy
Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy
The medical records of 393 eyes of 326 patients with severe proliferative diabetic retinopathy were reviewed. Higher cutting rate instruments (5000 cut per minute) were used in 174 eyes and conventional instruments in 219 eyes…
- Trial name
- NCT02464800
- Testing
- Vitrectomy for proliferative diabetic retinopathy
- Where
- Japan
- Volunteers
- 326 people
- Sponsor
- Kyorin University
Neovascular Glaucoma, Proliferative Diabetic Retinopathy
A Study on the Treatment Strategy of NVG Secondary to PDR
With the increasing incidence of proliferative diabetic retinopathy (PDR), subsequent neovascular glaucoma (NVG) has become one of the main causes of blindness in PDR patients, and the intraocular pressure of PDR patients with…
- Trial name
- NCT05156021
- Testing
- anti-VEGF
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ruijin Hospital
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
- Trial name
- NCT05393284
- Testing
- OPL-0401 Dose 1
- Where
- 25 sites in United States
- Volunteers
- 114 people
- Sponsor
- Valo Health, Inc.
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Diabetic Retinopathy
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18…
- Trial name
- POC1 (NCT00511875)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Gardner
Proliferative Diabetic Retinopathy, Vitrectomy
Macular Appearance After Diabetic Vitrectomy
Vitrectomy is one of the major treatment methods for complications of diabetic retinopathy. As surgical techniques and instruments improve, high anatomical success may be achieved; however, functional results are less favorable.
- Trial name
- NCT00737022
- Where
- Taiwan
- Volunteers
- 108 people
- Sponsor
- National Taiwan University Hospital
Proliferative Diabetic Retinopathy - High Risk
Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy
Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation.
- Trial name
- NCT06653361
- Testing
- Green laser
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Hayatabad Medical Complex
Diabetic Retinopathy, Diabetic Macular Edema
Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
Treatment of diabetic macular edema with perifoveal focal/grid laser coagulation was found to be effective saving the visual acuity only in 50% of patients and only 3-14% of treated patients had an improved visual acuity…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Proliferative Diabetic Retinopathy
- Trial name
- NCT00545870
- Testing
- bevacizumab, Ranibizumab
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Ursula Schmidt-Erfurth, M.D.
Proliferative Diabetic Retinopathy
Changes in Vitreous Temperature During Phacoemulsification
Temperature in the vitreous cavity decreases during vitrectomy, and the same effect is seen during an uneventful phaco surgery. Significant changes occur between the baseline temperature and after every step of the surgery.
- Trial name
- NCT01568242
- Testing
- Phacoemlsification
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Proliferative Diabetic Retinopathy, Vitrectomy
Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy
In recent years, vitrectomy has moved toward a minimally invasive vitrectomy surgery (MIV) system, which could effectively reduce the occurrence of operation complications, while reducing the time of post-operation recovery.
- Trial name
- NCT05446948
- Testing
- beveled 27G+ vitrectomy system, standard 25G+ vitrectomy system
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Eye Hospital
High Risk Proliferative Diabetic Retinopathy
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
This study is a prospective, randomized, multicentre, open label study that intents to compare the efficacy and safety of ranibizumab 0.5 mg Intravitreal (ITV) injections plus Panretinal Photocoagulation versus Panretinal…
- Trial name
- PROTEUS (NCT01941329)
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of ranibizumab
- Where
- 13 sites in France, Italy and 2 more
- Volunteers
- 94 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy
Treatment of severe proliferative diabetic retinopathy (PDR) may require the use of silicone oil for long-term retinal tamponade to prevent recurrent retinal detachment.
- Trial name
- NCT00596505
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- National Taiwan University Hospital
Diabetic Retinopathy
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults.
- Trial name
- NCT04552600
- Testing
- Nuvastatic
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Natureceuticals Sdn Bhd
Proliferative Diabetic Retinopathy (PDR)
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
The present study is intended to evaluate the safety and tolerability of topical OC-10X Ophthalmic Suspension in healthy human subjects. OcuCure Therapeutics, Inc.
- Trial name
- NCT01869933
- Testing
- OC-10X
- Where
- Bangladesh
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OcuCure Therapeutics, Inc.